Financials data is unavailable for this security.
View more
Year on year Nippon Shinyaku Co Ltd had relatively flat revenues (144.18bn to 148.26bn), though the company grew net income 13.32% from 22.81bn to 25.85bn. A reduction in the cost of goods sold as a percentage of sales from 38.83% to 33.88% was a component in the net income growth despite flat revenues.
| Gross margin | 66.81% |
|---|---|
| Net profit margin | 18.20% |
| Operating margin | 22.08% |
| Return on assets | 10.88% |
|---|---|
| Return on equity | 12.74% |
| Return on investment | 12.41% |
More ▼
Cash flow in JPYView more
In 2024, Nippon Shinyaku Co Ltd did not generate a significant amount of cash. However, the company earned 16.29bn from its operations for a Cash Flow Margin of 10.99%. In addition the company used 9.92bn on investing activities and also paid 9.72bn in financing cash flows.
| Cash flow per share | 484.35 |
|---|---|
| Price/Cash flow per share | 7.22 |
| Book value per share | 3,372.50 |
|---|---|
| Tangible book value per share | 2,935.46 |
More ▼
Balance sheet in JPYView more
| Current ratio | 4.87 |
|---|---|
| Quick ratio | 3.73 |
| Total debt/total equity | 0.0116 |
|---|---|
| Total debt/total capital | 0.0114 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.77% and 13.32%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.65% |
|---|---|
| Div growth rate (5 year) | 12.12% |
| Payout ratio (TTM) | 30.51% |
| EPS growth(5 years) | 9.66 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 17.39 |
More ▼
